Federal Register / Vol. 87, No. 112 / Friday, June 10, 2022 / Notices 35555 

FEDERAL RESERVE SYSTEM 

Change in Bank Control Notices; 

Acquisitions of Shares of a Bank or 

Bank Holding Company 

The notificants listed below have 

applied under the Change in Bank 

Control Act (Act) (12 U.S.C. 1817(j)) and 

§ 225.41 of the Board’s Regulation Y (12 

CFR 225.41) to acquire shares of a bank 

or bank holding company. The factors 

that are considered in acting on the 

applications are set forth in paragraph 7 

of the Act (12 U.S.C. 1817(j)(7)). 

The public portions of the 

applications listed below, as well as 

other related filings required by the 

Board, if any, are available for 

immediate inspection at the Federal 

Reserve Bank(s) indicated below and at 

the offices of the Board of Governors. 

This information may also be obtained 

on an expedited basis, upon request, by 

contacting the appropriate Federal 

Reserve Bank and from the Board’s 

Freedom of Information Office at 

https://www.federalreserve.gov/foia/ 

request.htm. Interested persons may 

express their views in writing on the 

standards enumerated in paragraph 7 of 

the Act. 

Comments regarding each of these 

applications must be received at the 

Reserve Bank indicated or the offices of 

the Board of Governors, Ann E. 

Misback, Secretary of the Board, 20th 

Street and Constitution Avenue NW, 

Washington, DC 20551–0001, not later 

than June 27, 2022. 

A. Federal Reserve Bank of St. Louis 

(Holly A. Rieser, Senior Manager) P.O. 

Box 442, St. Louis, Missouri 63166– 

2034 or by email at 

Comments.applications@stls.frb.org: 

1. The William A Carlson 2007 Trust, 

William A. Carlson and Pam Falkner, as 

co-trustees, Carlson Andrew Bennage, 

and Catherine Jane Carlson Bennage, all 

of West Memphis, Arkansas; Michael 

Dustin Carlson, two minor children of 

Michael Dustin Carlson, Marilyn Hayes 

Carlson, and Michael Andrew Carlson, 

all of Marion, Arkansas; Kirby Hayes 

Carlson, Proctor, Arkansas; and the 

William C. Carlson Living Trust, 

William C. Carlson, as trustee, Hot 

Springs, Arkansas; as members of a 

group acting in concert, to retain voting 

shares of Carlson Bancshares, Inc., and 

thereby indirectly retain voting shares of 

Fidelity Bank, West Memphis, 

Arkansas. 

B. Federal Reserve Bank of Kansas 

City (Jeffrey Imgarten, Assistant Vice 

President) 1 Memorial Drive, Kansas 

City, Missouri 64198–0001: 

1. The Luann M. Walker Trust, Luann 

Walker GST Management Trust, and 

Dale F. Walker GST Management Trust, 

Luann Walker as trustee of the 

aforementioned trusts, all of Ardmore, 

Oklahoma; Robert Keith Walker GST 

Management Trust, Ardmore, 

Oklahoma, Robert K. Walker, 

individually, and as trustee of the 

Robert Keith Walker GST Management 

Trust, and Christy Godwin, both of 

Denver, Colorado; and DFW Trust, 

Ardmore, Oklahoma, Dale Walker and 

Mary Walker, as co-trustees, both of 

Norman, Oklahoma; as a group acting in 

concert, to retain voting shares of First 

National Corporation of Ardmore, Inc., 

and thereby indirectly retain voting 

shares of First National Bank and Trust 

Company of Ardmore, both of Ardmore, 

Oklahoma. 

Board of Governors of the Federal Reserve 

System. 

Michele Taylor Fennell, 

Deputy Associate Secretary of the Board. 

[FR Doc. 2022–12593 Filed 6–9–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2019–0103] 

Reporting of Pregnancy Success Rates 

from Assisted Reproductive 

Technology (ART) Programs; 

Proposed Additional Data Collection 

Fields and Modified Reporting 

Requirements; Final Notice 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: General notice. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC) within 

the Department of Health and Human 

Services (HHS) announces revised plans 

for additional data fields and modified 

reporting requirements for Assisted 

Reproductive Technology (ART) 

programs pursuant to the Fertility Clinic 

Success Rate and Certification Act of 

1992 (FCSRCA). This notice also 

responds to public comments received 

in response to CDC’s 2019 request for 

comment. 

DATES: The requirements for the 

additional data fields and modified 

reporting requirements will be 

implemented for reporting year 2021. 

FOR FURTHER INFORMATION CONTACT: 

Mithi Sunderam, Division of 

Reproductive Health, National Center 

for Chronic Disease Prevention and 

Health Promotion, Centers for Disease 

Control and Prevention, 4770 Buford 

Highway NE, Mailstop S107–2, Atlanta, 

Georgia 30341; Telephone: 1–800–232– 

4636; Email: ARTinfo@cdc.gov. 

SUPPLEMENTARY INFORMATION: On 

November 6, 2019, CDC published a 

notice in the Federal Register (84 FR 

59814) requesting comments on a plan 

proposing that ART programs collect 

additional information, listed below. 

(i) For intended parents who are not 

oocyte source or pregnancy carriers 

under Section A (Patient Demographic 

Information): race/ethnicity. 

(ii) For oocyte donors under Section 

D (Oocyte Source and Carrier 

Information): height, weight, smoking 

history, and other key pregnancy, 

diagnostic, and reproductive history 

(including number of prior pregnancies 

[ectopic, spontaneous abortions]; 

number of prior births [full term, 

preterm, live births, stillbirths]; history 

of prior ART cycles [fresh, frozen]; 

maximum follicle-stimulating hormone 

(FSH) level [value in mIU/mL]; and 

most recent anti-mu ̈llerian hormone 

(AMH) level [value in ng/mL, date]). 

(iii) For both fresh embryo transfers 

and thawed embryo transfers, under 

Section H (Transfer Information): clinic 

names if oocyte retrievals took place in 

a clinic different from the one 

performing the transfer. 

CDC also proposed changes in 

reporting responsibilities when multiple 

ART programs were involved in 

performing one cycle (such as different 

ART programs responsible for ovarian 

stimulation, oocyte retrieval, and/or 

embryo transfer), moving the reporting 

obligations from the ART program that 

accepts responsibility for embryo 

culture to the ART program that directs 

the clinical management of the cycle. 

Public Comment Summary and 

Responses 

CDC received three comments (two 

comments from researchers and one 

from the Society for Assisted 

Reproductive Technology) in response 

to its request for comment. Summaries 

of these comments and CDC’s responses 

are provided below. 

1. One commenter cautioned that 

embryos shipped between centers often 

arrive without retrieval information, 

such as dates of retrieval. The 

commenter was otherwise supportive of 

collecting additional information for 

embryos shipped from different centers, 

as it would improve the accuracy of 

calculating cumulative success rates. 

Response: CDC thanks the commenter 

for providing this comment. Accurate 

documentation of oocyte retrieval dates 

is important for establishing cumulative 


jspears on DSK121TN23PROD with NOTICES1
35556 Federal Register / Vol. 87, No. 112 / Friday, June 10, 2022 / Notices 

success rates. No changes were made to 

the reporting requirement. 

2. A second commenter suggested 

using the term ‘‘intended parents’’ 

rather than ‘‘patients’’ for people who 

are not using their own oocytes or 

carrying a pregnancy. The commenter 

supported collection of additional 

information for oocyte donors and 

suggested expanding data collection to 

reflect changes in ART practice by 

collecting additional information (such 

as reproductive health and history, 

demographics, and detailed information 

on prior ART treatments) for all people 

involved in an ART cycle, including 

both intended parents and gestational 

carriers. The commenter also proposed 

that independent egg freezing clinics or 

companies that are not affiliated with 

ART clinics should be required to report 

their data. Finally, the commenter had 

many suggestions for improving the data 

collected by the Society for Assisted 

Reproductive Technology. 

Response: CDC thanks the commenter 

for these suggestions. CDC agrees that 

the suggested terminology (‘‘intended 

parents’’) is more accurate. No changes 

were made to the reporting 

requirements based on these comments; 

however, CDC will adopt the term 

‘‘intended parents’’ where appropriate. 

Any practice, program, or clinic 

providing ART services (such as egg 

freezing) is required to report its data to 

CDC whether or not it is affiliated with 

an ART clinic. Specifics about the 

reporting process and requirements are 

described in ‘‘Reporting of Pregnancy 

Success Rates from Assisted 

Reproductive Technology (ART) 

Programs’’ (80 FR 51811). Therefore, no 

changes to the reporting requirements 

are needed based on these comments. 

3. A third commenter expressed 

concerns about the burden of additional 

data collection on reporting clinics. The 

commenter also noted that additional 

variables related to egg donors may not 

have an impact on pregnancy outcomes, 

which is the primary focus of FCSRCA. 

Additionally, the commenter noted that 

CDC’s plan to collect information on 

race/ethnicity for intended parents 

using donor oocytes and gestational 

carriers was mainly for research 

purposes, as these variables have no 

biological effect on pregnancy 

outcomes. 

Response: CDC thanks the commenter 

for providing their feedback. Since the 

proposed additional information related 

to egg donors is already collected during 

the time of egg retrieval, CDC will 

instead link the information collected 

during egg retrieval from the clinic that 

performed the egg retrieval with 

information reported during donor egg 

or embryo transfer from the ART clinic 

performing the transfer. This can be 

achieved by transmitting the cycle 

identification number from the clinic 

that collected the donor egg to the clinic 

that provides care to the donor egg 

recipient. This will allow utilization of 

the data that are already collected to 

avoid additional burden on clinics. The 

details of the proposed linkage plan will 

be published separately in a different 

Federal Register notice before 

implementation. 

CDC notes the commenter’s feedback 

regarding collecting information on 

race/ethnicity for a small group of 

intended parents that do not use their 

own eggs or carry a pregnancy. Other 

demographic information such as date 

of birth, sex, and residency status are 

currently collected for this group; 

however, information on race/ethnicity 

is currently only collected for oocyte 

sources and pregnancy carriers. 

Collecting information on race/ethnicity 

for both intended parents that do not 

use their own eggs or carry pregnancy, 

and for oocyte sources and pregnancy 

carriers, ensures consistency in 

demographic data collection. CDC also 

believes that this information allows the 

pregnancy success rates to reflect a 

complete set of demographics for 

intended parents and will help better 

understand disparities in utilization of 

ART services. 

Please see the revised Appendix 

below for the new requirements. 

Appendix—Notice for Reporting of 

Pregnancy Success Rates From Assisted 

Reproductive Technology (ART) 

Programs; Additional Data Collection 

Fields and Modified Reporting 

Requirements: 

A. Background 

On August 26, 2015, CDC published a 

notice in the Federal Register (80 FR 51811) 

announcing the overall reporting 

requirements of the National ART 

Surveillance System (NASS). The notice 

described who shall report to HHS/CDC; the 

process for reporting by each ART program; 

the data to be reported; and the contents of 

the published reports. This data collection is 

approved under Office of Management and 

Budget Control Number 0920–0556, 

expiration date: 12/31/2024. The purpose of 

this notice published June 10, 2022 is to 

apply consistent data collection requirements 

to various treatment options, including 

certain rare situations, to improve quality of 

data. Effective for reporting year 2021, CDC 

is implementing the following changes to its 

data collection. 

Section III. What to Report 

Section A. Patient Demographic Information 

Addition (for Intended Parents Who Are Not 

Oocyte Source or Pregnancy Carrier) 

In addition to collecting information on 

race and ethnicity for oocyte source, sperm 

source, and pregnancy carrier as part of the 

current data collection system, CDC will also 

collect race and ethnicity information for 

intended parents who do not use their own 

oocytes (use donor eggs) and do not carry the 

pregnancy (use gestational carrier). 

Specifically, this information will include (i) 

Ethnicity (Hispanic, non-Hispanic, Refused, 

Unknown) and (ii) Race (White, Black, Asian, 

Native Hawaiian/Pacific Islander, American 

Indian or Alaska Native, Refused, Unknown). 

CDC has added these questions to the patient 

profile in the beginning of the questionnaire 

to ensure consistency in demographic data 

collected and to allow the pregnancy success 

rates to reflect a complete set of 

demographics for intended parents. To 

reduce the reporting burden, the system has 

been designed to pre-fill race/ethnicity of 

oocyte source, sperm source, or pregnancy 

carrier, if previously reported. 

Section D. Oocyte Source and Carrier 

Information 

Addition (for Oocyte Donors) 

CDC has replaced its original plan to add 

several new data collection fields for oocyte 

donors which were to be obtained directly 

from ART programs. Instead, CDC plans to 

use the oocyte donor cycle identifying 

information to link and retrieve information 

about oocyte donors collected at the time of 

egg retrieval. When applicable, oocyte donor 

cycle identifying information will be 

transferred from the program involved in egg 

retrieval to the program involved in 

subsequent use of donor eggs. The details of 

the proposed linkage plan and the timeline 

for implementation of this plan will be 

published in a separate Federal Register 

notice before implementation. 

Section H. Transfer Information 

Addition (if Oocyte Retrieval Was Not 

Conducted at the Same Clinic as Transfer) 

CDC will collect the name of the clinic in 

which the previous egg retrieval occurred for 

all fresh embryo transfers and thawed 

embryo transfers if the retrieval and transfer 

were completed at different clinics. Oocyte 

retrieval dates are already being collected for 

all transferred embryos. 

Reporting Requirement Modification 

Section I. Who Reports 

Sub-Section C. Reporting Responsibilities of 

ART Program 

Modification (if More Than One Program is 

Involved in One Cycle) 

Multiple ART programs involved in one 

cycle — Different ART programs responsible 

for ovarian stimulation, oocyte retrieval, and/ 

or embryo transfer. 

The following updated guidelines shall be 

used: 

a. The requirement to report cycles lies 

with the ART program that directs the 


jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 112 / Friday, June 10, 2022 / Notices 35557 

clinical management of the cycle, which 

would include (but is not limited to) multiple 

aspects of the treatment such as patient 

selection, pre-treatment counseling and 

selection of the specific treatment protocol. 

The ART programs involved must have a 

method in place to ensure that these cycles 

can be prospectively reported by the ART 

program required to report them. In addition, 

all canceled cycles must be reported by the 

same ART program. 

b. Cycles involving previously 

cryopreserved oocytes/embryos are to be 

reported by the ART program that accepts 

responsibility for thawing the oocytes/ 

embryos. 

Dated: June 7, 2022. 

Angela K. Oliver, 

Executive Secretary, Centers for Disease 

Control and Prevention. 

[FR Doc. 2022–12528 Filed 6–9–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Submission for OMB Review; 

Behavioral Interventions To Advance 

Self-Sufficiency Next Generation 

(BIAS–NG) (OMB# 0970–0502) 

AGENCY: Office of Planning, Research, 

and Evaluation, Administration for 

Children and Families, HHS. 

ACTION: Request for public comment. 

SUMMARY: The Office of Planning, 

Research, and Evaluation (OPRE) in the 

Administration for Children and 

Families (ACF), U.S. Department of 

Health and Human Services (HHS), 

requests Office of Management and 

Budget (OMB) approval to extend 

approval of the ACF Behavioral 

Interventions to Advance SelfSufficiency Next Generation (BIAS–NG) 

Project Overarching Generic (OMB #: 

0970–0502; Expiration date: 8/31/2022). 

Under this overarching generic, ACF 

collects data as part of rapid cycle 

testing and evaluation, in order to 

inform the design of interventions 

informed by behavioral science and to 

better understand the mechanisms and 

effects of such interventions. 

Interventions have been and will 

continue to be developed in the program 

area domains of Temporary Assistance 

for Needy Families (TANF), child 

welfare, and Early Head Start/Head Start 

(EHS/HS). These interventions are 

intended to improve outcomes for 

participants in these programs. No 

changes are proposed. 

DATES: Comments due within 30 days of 

publication. OMB must make a decision 

about the collection of information 

between 30 and 60 days after 

publication of this document in the 

Federal Register. Therefore, a comment 

is best assured of having its full effect 

if OMB receives it within 30 days of 

publication. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. You can also obtain 

copies of the proposed collection of 

information by emailing 

OPREinfocollection@acf.hhs.gov. 

Identify all requests by the title of the 

information collection. 

SUPPLEMENTARY INFORMATION: 

Description: OPRE is conducting the 

BIAS–NG project, which uses 

behavioral insights to design and test 

interventions intended to improve the 

efficiency, operations, and efficacy of 

human services programs. The BIAS– 

NG project is applying and testing 

behavioral insights to ACF programs 

including TANF, Child Welfare, and 

EHS/HS. This notice is a request for 

comments on ACF’s proposal to extend 

approval of the overarching generic. 

Under the approved pilot generic 

clearance, OPRE has already completed 

work with five sites and has conducted 

five tests. The extended approval would 

allow OPRE to continue to work with at 

least three additional sites, conducting 

one or more tests of behavioral 

interventions. The design and testing of 

BIAS–NG interventions is rapid and, to 

the extent possible, iterative. Each 

specific intervention is designed in 

consultation with agency leaders and 

launched as quickly as possible. To 

maximize the likelihood that the 

intervention produces measurable, 

significant, and positive effects on 

outcomes of interest, rapid cycle 

evaluation techniques will be employed 

in which proximate outcomes will be 

measured to allow the research team to 

more quickly iterate and adjust the 

intervention design, informing 

subsequent tests. Due to the rapid and 

iterative nature of this work, OPRE 

sought and received generic clearance to 

conduct this research. Following 

standard OMB requirements for generic 

clearances, once instruments requiring 

burden are tailored to a specific site and 

the site’s intervention, OPRE submits an 

individual generic information 

collection request under this umbrella 

clearance. Each request includes the 

individual instrument(s), a justification 

specific to the individual information 

collection, a description of the proposed 

intervention, and any supplementary 

documents. Each specific information 

collection includes up to two 

submissions—one submission for the 

formative stage research and another 

submission for any further data 

collection requiring burden during the 

testing phase. The type of information to 

be collected and the uses of the 

information is described in the 

supporting statements, found here: 

https://www.reginfo.gov/public/do/ 

PRAViewICR?ref_nbr=201909-0970-003. 

Respondents: (1) Program 

Administrators, (2) Program Staff, and 

(3) Program Clients. 

Annual Burden Estimates (TANF, CW, 

EHS/HS): This request includes an 

extension to complete currently 

approved and ongoing phase 3 data 

collection in three sites (Matrix/Starfish 

and Hennepin County), and new data 

collection. Burden estimates for new 

requests are outlined below. Previously 

approved burden estimates can be found 

at the url above. 

Instrument 

Number of 

respondents 

(TANF, CW, 

EHS/HS) 

(total over 

request 

period) 

Number of 

responses per 

respondent 

(total over 

request 

period) 

Average 

burden hours 

per response 

(in hours) 

Total burden 

(in hours) 

Annual burden 

(in hours) 

Phase 3: Diagnosis and Design 

Administrator interviews/focus groups ................................. 48 1 1 48 16 

Staff interviews/focus groups ............................................... 400 1 1 400 133 

Client interviews/focus groups ............................................. 400 1 1 400 133 

Client survey ........................................................................ 400 1 0.25 100 33 


jspears on DSK121TN23PROD with NOTICES1